These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Treatment of Langerhans cell histiocytosis with a modified risk-adapted protocol-experience from a tertiary cancer institute in India. Narula G; Pradhan ND; Arora B; Banavali SD Pediatr Blood Cancer; 2018 Aug; 65(8):e27028. PubMed ID: 29512864 [TBL] [Abstract][Full Text] [Related]
5. [Treatment results of Langerhans cell histiocytosis with LSH II protocol]. Mottl H; Ganevová M; Radvanská J; Chánová M; Smelhaus V; Kodet R; Mrhalová M; Tichý M Cas Lek Cesk; 2005; 144(11):753-5. PubMed ID: 16335702 [TBL] [Abstract][Full Text] [Related]
6. Diabetes insipidus in Langerhans cell histiocytosis: results from the DAL-HX 83 study. Grois N; Flucher-Wolfram B; Heitger A; Mostbeck GH; Hofmann J; Gadner H Med Pediatr Oncol; 1995 Apr; 24(4):248-56. PubMed ID: 7700170 [TBL] [Abstract][Full Text] [Related]
7. Multisystem Langerhans cell histiocytosis in children: current treatment and future directions. Minkov M Paediatr Drugs; 2011 Apr; 13(2):75-86. PubMed ID: 21351807 [TBL] [Abstract][Full Text] [Related]
8. Intensification of induction therapy and prolongation of maintenance therapy did not improve the outcome of pediatric Langerhans cell histiocytosis with single-system multifocal bone lesions: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study. Morimoto A; Shioda Y; Imamura T; Kudo K; Kitoh T; Kawaguchi H; Goto H; Kosaka Y; Tsunematsu Y; Imashuku S; Int J Hematol; 2018 Aug; 108(2):192-198. PubMed ID: 29594922 [TBL] [Abstract][Full Text] [Related]
9. Outcome of children with Langerhans cell histiocytosis and single-system involvement: A retrospective study at a single center in Shanghai, China. Su M; Gao YJ; Pan C; Chen J; Tang JY Pediatr Hematol Oncol; 2018; 35(7-8):385-392. PubMed ID: 30693828 [TBL] [Abstract][Full Text] [Related]
10. Outcomes of children younger than 24 months with langerhans cell histiocytosis and bone involvement: a report from a single institution. Kamath S; Arkader A; Jubran RF J Pediatr Orthop; 2014 Dec; 34(8):825-30. PubMed ID: 25387157 [TBL] [Abstract][Full Text] [Related]
11. Acute leukemia in association with Langerhans cell histiocytosis. Egeler RM; Neglia JP; Aricò M; Favara BE; Heitger A; Nesbit ME Med Pediatr Oncol; 1994; 23(2):81-5. PubMed ID: 8202046 [TBL] [Abstract][Full Text] [Related]
13. Comparison of vindesine and prednisone and cyclophosphamide, etoposide, vindesine, and prednisone as first-line treatment for adult Langerhans cell histiocytosis: A single-center retrospective study. Duan MH; Han X; Li J; Zhang W; Zhu TN; Han B; Zhuang JL; Wang SJ; Cao XX; Cai HC; Chen M; Yang C; Zhou DB Leuk Res; 2016 Mar; 42():43-6. PubMed ID: 26859782 [TBL] [Abstract][Full Text] [Related]
14. [Lenalidomide induced therapeutic response in a patient with aggressive multi-system Langerhans cell histiocytosis resistant to 2-chloro-deoxyadenosine and early relapsing after high-dose BEAM chemotherapy with autologous peripheral blood stem cell transplantation]. Adam Z; Rehák Z; Koukalová R; Szturz P; Krejčí M; Pour L; Zahradová L; Moulis M; Kodet R; Nebeský T; Brejcha M; Adamová Z; Hájek R; Mayer J Vnitr Lek; 2012 Jan; 58(1):62-71. PubMed ID: 22448704 [TBL] [Abstract][Full Text] [Related]
16. Pattern and course of single-system disease in Langerhans cell histiocytosis data from the DAL-HX 83- and 90-study. Titgemeyer C; Grois N; Minkov M; Flucher-Wolfram B; Gatterer-Menz I; Gadner H Med Pediatr Oncol; 2001 Aug; 37(2):108-14. PubMed ID: 11496348 [TBL] [Abstract][Full Text] [Related]
17. Therapeutic outcome of multifocal Langerhans cell histiocytosis in adults treated with the Special C regimen formulated by the Japan LCH Study Group. Morimoto A; Shimazaki C; Takahashi S; Yoshikawa K; Nishimura R; Wakita H; Kobayashi Y; Kanegane H; Tojo A; Imamura T; Imashuku S; Int J Hematol; 2013 Jan; 97(1):103-8. PubMed ID: 23243004 [TBL] [Abstract][Full Text] [Related]
18. Response to initial treatment of multisystem Langerhans cell histiocytosis: an important prognostic indicator. Minkov M; Grois N; Heitger A; Pötschger U; Westermeier T; Gadner H; Med Pediatr Oncol; 2002 Dec; 39(6):581-5. PubMed ID: 12376981 [TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics and treatment outcome of Langerhans cell histiocytosis: 22 years' experience of 154 patients at a single center. Lee JW; Shin HY; Kang HJ; Kim H; Park JD; Park KD; Kim HS; Park SH; Wang KC; Ahn HS Pediatr Hematol Oncol; 2014 Apr; 31(3):293-302. PubMed ID: 24397251 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]